FAQ on Calidi Biotherapeutics Inc.'s $4.6 Million Warrant Exercise Agreement

What is the main purpose of Calidi Biotherapeutics Inc.’s recent financial move?

The main purpose is to raise approximately $4.6 million in gross proceeds through the immediate cash exercise of outstanding warrants, which will support the company’s clinical and pre-clinical programs, operations, and working capital.

How much money is Calidi Biotherapeutics Inc. expecting to generate from this agreement?

Calidi Biotherapeutics Inc. is expecting to generate approximately $4.6 million in gross proceeds from this agreement.

What are the terms of the new warrants issued by Calidi Biotherapeutics Inc.?

The new warrants are unregistered, exercisable in six months at $0.70 per share, and valid for five and a half years.

Who is serving as the exclusive placement agent for this transaction?

Ladenburg Thalmann & Co. Inc. is serving as the exclusive placement agent for this transaction.

What does Calidi Biotherapeutics Inc. specialize in?

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer, utilizing novel stem cell-based platforms for delivering oncolytic viruses.

Where can I find more information about Calidi Biotherapeutics Inc.?

More information can be found on the company’s website at www.calidibio.com or in the company’s newsroom at https://ibn.fm/CLDI.

What is the significance of this financial move for Calidi Biotherapeutics Inc.?

This move is significant as it provides the company with necessary funds to advance its clinical and pre-clinical programs, enhancing its ability to develop targeted therapies for genetic medicine delivery.

How does Calidi Biotherapeutics Inc.’s technology work?

Calidi’s technology uses allogeneic stem cells to carry payloads of oncolytic viruses, designed to protect, amplify, and potentiate these viruses for enhanced efficacy and improved patient safety in treating cancer.